Last Updated : September 28, 2023
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Vraylar | cariprazine | Schizophrenia | Do not reimburse | Complete | ||
| Vyalev | foslevodopa foscarbidopa | Parkinson's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vyepti | eptinezumab | Migraine | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vyndaqel | tafamidis | Transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vyndaqel | tafamidis | transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vyvanse | Lisdexamfetamine dimesylate | Attention deficit hyperactivity disorder | Do not list | Complete | ||
| Vyvgart | efgartigimod alfa | Generalized myasthenia gravis (gMG) | Active | |||
| Vyxeos | daunorubicin and cytarabine | Acute myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vyzulta | latanoprostene bunod | Open-angle glaucoma or ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
| Wakix | pitolisant hydrochloride | Narcolepsy | Do not reimburse | Complete |
Last Updated : September 28, 2023